USANA Health Sciences (NYSE:USNA) Updates FY 2026 Earnings Guidance

Posted by Geri Gentry on May 5th, 2026

USANA Health Sciences (NYSE:USNA – Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.950-2.290 for the period, compared to the consensus earnings per share estimate of 1.950. The company issued revenue guidance of $925.0M-$1.0 billion, compared to the consensus revenue estimate of $938.7 million.

USANA Health Sciences Stock Performance

USANA Health Sciences stock traded up $0.63 during trading on Tuesday, reaching $19.19. 97,344 shares of the company’s stock were exchanged, compared to its average volume of 96,955. The company’s 50-day moving average is $18.53 and its two-hundred day moving average is $19.72. USANA Health Sciences has a 52-week low of $16.60 and a 52-week high of $38.32. The firm has a market cap of $354.19 million, a price-to-earnings ratio of 34.89, a PEG ratio of 0.79 and a beta of 0.77.

USANA Health Sciences (NYSE:USNA – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to the consensus estimate of $240.99 million. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Analysts anticipate that USANA Health Sciences will post 1.95 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on USNA shares. Zacks Research downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Wall Street Zen downgraded USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, USANA Health Sciences has an average rating of “Reduce”.

Check Out Our Latest Analysis on USNA

Insider Activity at USANA Health Sciences

In other news, insider Joshua Foukas sold 4,461 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.82% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

Several large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its position in shares of USANA Health Sciences by 4.6% during the fourth quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after purchasing an additional 542 shares during the last quarter. Quantbot Technologies LP lifted its position in shares of USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after purchasing an additional 646 shares during the last quarter. Intech Investment Management LLC lifted its position in shares of USANA Health Sciences by 13.5% during the third quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock worth $213,000 after purchasing an additional 918 shares during the last quarter. National Bank of Canada FI lifted its position in shares of USANA Health Sciences by 166.6% during the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of USANA Health Sciences by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

(Get Free Report)

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.